Pfizer's Read in Tokyo: No AZ clues but PD-L1 draws explained
This article was originally published in Scrip
Executive Summary
If its recent potential multi-billion dollar deal for Merck KGaA's anti-PD-L1 antibody has affected Pfizer's interest in AstraZeneca as a possible takeover target, the US firm's chairman and CEO is giving nothing away.